Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.80 USD

28.80
8,463,199

-0.29 (-1.00%)

Updated Sep 30, 2024 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Pfizer (PFE) Seeks FDA Approval for Omicron Booster in Kids

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech seek authorization from the FDA for using their bivalent COVID-19 booster vaccine in kids. The vaccine is already authorized for use in adolescents and adults.

Pfizer (PFE) Stock Moves -0.57%: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $43.83, moving -0.57% from the previous trading session.

Valneva (VALN) Stock Down 66% in the Past 6 Months: Here's Why

by Zacks Equity Research

Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.

Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK

by Zacks Equity Research

The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.

Why Novavax (NVAX) Stock Was Down 13% on Thursday

by Zacks Equity Research

Novavax (NVAX) sinks to a new record level 52-week low after analysts at JP Morgan cut the 12-month target price on the stock by more than $100.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

by Zacks Equity Research

Sector ETF report for FHLC

The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax

by Zacks Equity Research

Pfizer, BioNTech, Moderna and Novavax are included in this Analyst Blog.

Pfizer (PFE) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $44.77, moving -1.47% from the previous trading session.

Kinjel Shah headshot

Vaccine Stocks Down After Biden Says Pandemic is Over

by Kinjel Shah

BioNTech (BNTX), Moderna (MRNA) and Novavax (NVAX) stocks decline 8.6%, 7.1% and 6.5%, respectively.

Merck's (MRK) Pneumococcal Jab Gets CHMP Endorsement for Kids

by Zacks Equity Research

The EMA's CHMP recommends approving Merck's (MRK) pneumococcal 15-valent conjugate vaccine for expanded use in infants and children. The vaccine received similar approval from the FDA in June 2022.

Zacks Investment Ideas feature highlights: Pfizer, Apple and Alphabet

by Zacks Equity Research

Pfizer, Apple and Alphabet have been highlighted in this Investment Ideas article.

Pfizer's (PFE) Late-Stage Meningococcal Jab Study Meets Goal

by Zacks Equity Research

Based on positive top-line data from phase III on its pentavalent meningococcal vaccine, Pfizer (PFE) intends to submit a regulatory application to the FDA seeking approval by year-end.

Kinjel Shah headshot

Pharma Stock Roundup: J&J New Buyback Plan, CHMP Nod to PFE's BA.4, BA.5 Omicron Jab

by Kinjel Shah

J&J (JNJ) announces a new $5 billion stock buyback plan. CHMP recommends authorizing Pfizer's (PFE) Omicron BA.4 and BA.5 boosters in Europe.

Is Trending Stock Pfizer Inc. (PFE) a Buy Now?

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Derek Lewis headshot

3 Mega-Cap Stocks With Unbelievably Strong Free Cash Flow

by Derek Lewis

All three companies generate substantial cash. In fact, one reported the highest quarterly free cash flow of any S&P 500 company in Q2.

Pfizer (PFE) Starts Late-Stage Study on Influenza Vaccine

by Zacks Equity Research

Pfizer (PFE) doses the first participants in the phase III study of its investigational mRNA-based influenza vaccine. The study will enroll nearly 25,000 participants.

Zacks Market Edge Highlights: 3M, Northwest Bancshares, Pfizer, Xerox, Enterprise Products Partners

by Zacks Equity Research

3M, Northwest Bancshares, Pfizer, Xerox, Enterprise Products Partners have been highlighted in this Market Edge article.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $46.15, moving -0.09% from the previous trading session.

Tracey Ryniec headshot

How to Have Fun Investing

by Tracey Ryniec

Get paid for being an owner of a business. Collect those dividend checks and watch them compound.

Pfizer (PFE), BioNTech Omicron BA.4, BA.5 Boosters Get CHMP Nod

by Zacks Equity Research

Pfizer (PFE) and BioNTech (BNTX) get a positive recommendation from CHMP for Omicron BA.4 and BA.5-adapted bivalent vaccines.

Novavax (NVAX) Gets EU Nod for COVID-19 Booster Jab in Adults

by Zacks Equity Research

Novavax (NVAX) gets authorization from the European Union to use its COVID-19 vaccine as a booster dose in adults.

Ideaya (IDYA) Up on Interim Data from Mid-Stage Eye Cancer Study

by Zacks Equity Research

Ideaya Biosciences (IDYA) reports positive interim results from its mid-stage study, evaluating darovasertib in combination with Pfizer's Xalkori (crizotinib) in metastatic uveal melanoma. Stock up.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE